Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1NET 1Head & Neck 1Gastrointestinal 1Endocrine 1

Conditions

Small Cell Lung Carcinoma 7Carcinoma, Non-Small-Cell Lung 3Stomach Neoplasms 2Thyroid Carcinoma, Anaplastic 1Sarcoma 1Neuroendocrine Tumors 1Neoplasm Metastasis 1NSCLC 1Colorectal Neoplasms 1Advanced Non-Small Cell Lung Cancer 1

Interventions

dabrafenib 2Trastuzumab 2zimberelimab 1vandetanib 1trametinib 1tislelizumab 1tipifarnib 1surufatinib 1spartalizumab 1sargramostim 1cobimetinib 1aldesleukin 1Vemurafenib 1Tamoxifen 1Radiotherapy 1PLX8394 1Interleukin-12 Subunit p35 1Interleukin-12 1Gefitinib 1Doxorubicin 1Docetaxel 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Carcinoma, Anaplastic × surufatinib × Thoracic × Clear all
NCT04579757 2025-05-08

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Hutchmed

Phase 1/2 Terminated
87 enrolled 29 charts
EndocrineGastrointestinalHead & NeckNETSarcomaThoracic

Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors, Small Cell Lung Carcinoma, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡